Can You Take Retatrutide Orally?

Retatrutide is an investigational medicine being studied for obesity and type 2 diabetes, and a common question is whether it can be taken orally. Currently, no oral formulation of retatrutide has been evaluated in published human clinical trials. All available trial data involve subcutaneous injection. This article explains how retatrutide works, what the clinical trial evidence says about its formulation, what side effects have been reported, and why no tablet or pill form is currently available or authorised anywhere in the world.

What is retatrutide and how does it work?

Retatrutide is an investigational medicine that simultaneously activates GLP-1, GIP, and glucagon receptors, influencing appetite, energy expenditure, and glucose metabolism. It holds no marketing authorisation and is available only within an authorised clinical trial.

Retatrutide is an investigational medicine being studied for the treatment of obesity and type 2 diabetes, but it does not currently hold a marketing authorisation in the UK or anywhere else in the world.^[12][1] It works by activating three hormone receptors simultaneously: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. GLP-1 and GIP are incretin hormones, so their receptor pathways are incretin-mediated; glucagon receptor agonism is a distinct, non-incretin mechanism. This triple-receptor activity distinguishes retatrutide from currently licensed medicines such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GIP and GLP-1 receptor agonist), though no head-to-head trials have compared these treatments directly.^[5][10]

By engaging all three receptors, retatrutide is thought to influence appetite regulation, energy expenditure and glucose metabolism through complementary pathways. The glucagon receptor component, in particular, may contribute to increased energy use, a mechanism not shared by the currently licensed injectable weight-management medicines. However, because retatrutide has not received regulatory authorisation, these mechanisms remain under active investigation and no conclusions about its clinical role can yet be drawn.

Retatrutide is available only within an authorised clinical trial. It is not available through any pharmacy, clinic or online supplier, and anything sold online under this name is not a licensed product and may be falsified. People interested in licensed weight-management treatments are encouraged to speak with their GP.

What do clinical trials say about retatrutide's formulation?

All published clinical trials, including the Phase 2 study in the New England Journal of Medicine (2023), have evaluated retatrutide exclusively as a once-weekly subcutaneous injection. No oral formulation has been studied in human trials.

Clinical trial data published to date indicate that retatrutide has been studied exclusively as a subcutaneous injection, meaning it is administered under the skin rather than taken by mouth. The Phase 2 trial published in the New England Journal of Medicine in 2023 evaluated retatrutide given as a once-weekly subcutaneous injection across a range of doses in adults with obesity, reporting findings on body weight reduction and tolerability over 48 weeks.^[1][2] Those results reflect a controlled trial setting and cannot be generalised to broader clinical use.

Phase 3 evaluation is under way across the TRIUMPH programme (obesity) and the TRANSCEND series (including TRANSCEND-T2D-1 in type 2 diabetes), studying retatrutide in its injectable subcutaneous form across larger and more diverse populations.^[3] Some Phase 3 topline results have been reported at scientific congresses, though full peer-reviewed publications are still emerging; any 'ongoing' phrasing in this article reflects the position at the time of writing and readers should check current sources for the latest data.

No published trial data have evaluated an oral formulation of retatrutide in humans, and no oral retatrutide arm has been identified in publicly available trial registries at the time of writing. The development of oral versions of incretin-based medicines is an active area of pharmaceutical research more broadly, but no oral retatrutide formulation has been reported in peer-reviewed clinical trial results.

Because retatrutide holds no marketing authorisation, its evidence base is still accumulating, and regulatory agencies including the MHRA have not yet assessed it for approval. The formulation, dosing and safety profile that would accompany any future application remain subject to ongoing evaluation.

What are the known side effects and safety concerns to be aware of?

The most commonly reported side effects in Phase 2 trials were gastrointestinal, including nausea, vomiting, diarrhoea, and constipation, typically occurring during dose escalation. The full safety profile remains under investigation as retatrutide is not yet authorised.

The safety profile of retatrutide, as reported in the Phase 2 trial and associated publications, shows a pattern broadly consistent with other medicines in this class, though the data are limited by the size and duration of trials conducted so far. The most commonly reported adverse effects in the Phase 2 trial were gastrointestinal in nature, including nausea, vomiting, diarrhoea and constipation. These effects were generally more frequent at higher doses and tended to occur during the dose-escalation period.

As with other medicines in this class, there are theoretical concerns about effects on the pancreas. The UK SmPCs for related licensed medicines note that acute pancreatitis has been reported, including post-marketing reports of necrotising pancreatitis and reports with a fatal outcome, though no risk magnitude is established.^[4][5] Whether retatrutide carries a comparable risk is not yet known from the available trial data. Participants in retatrutide trials have also been monitored for heart rate changes, as glucagon receptor activation may influence cardiovascular parameters.

Because retatrutide is investigational, its full safety profile is not yet established. People who are pregnant, breastfeeding or planning a pregnancy are excluded from retatrutide trials, and appropriate contraception is required for trial participation.

Anyone enrolled in a retatrutide clinical trial should follow the study protocol for reporting suspected adverse events, which means contacting the trial team in the first instance. Trial participants should also carry their trial documentation and inform any emergency or urgent care clinician that they are enrolled in a trial, so that appropriate decisions can be made about their care. If you develop severe or persistent upper abdominal pain, with or without vomiting, contact your GP or call NHS 111 for urgent advice. Suspected side effects of any medicine can also be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Can retatrutide be taken as a tablet or pill?

No oral formulation of retatrutide has been evaluated in published human clinical trials, and it is not available in tablet or pill form. Any product sold online as oral retatrutide is not a licensed medicine and may be falsified or unsafe.

No oral formulation of retatrutide has been evaluated in published human clinical trials, and retatrutide is not currently available in tablet or pill form. All clinical trial data to date involve subcutaneous injection, and no oral retatrutide arm has been identified in publicly available trial registries at the time of writing. The question of oral delivery is scientifically relevant because peptide-based medicines are typically broken down in the digestive system before they can be absorbed, which makes oral formulation technically challenging.^[8]

For context, the development of oral incretin therapies is an active area of broader pharmaceutical research. Oral semaglutide for weight management, marketed as Wegovy 25 mg tablets, received MHRA authorisation on 11 June 2026 and is a distinct product from Rybelsus, with its own licensed posology (starting dose 1.^[6]5 mg, escalating to a maintenance dose of 25 mg). However, this does not mean that an oral version of retatrutide is in development or imminent, and no such product has been announced or evaluated in trials reported in the public domain.

Retatrutide itself holds no marketing authorisation in the UK, and no timeline for any regulatory submission can be given. It is available only within an authorised clinical trial, regardless of formulation. Anyone who encounters a product described as oral retatrutide being sold online should be aware that it is not a licensed medicine and may be falsified or unsafe. People seeking licensed options for weight management should speak with their GP, who can discuss treatments that have been authorised by the MHRA and recommended through appropriate NHS guidance.

Frequently Asked Questions